ImpediMed Ltd
ASX:IPD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (25.5), the stock would be worth AU$-0.26 (1 944% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.4 | AU$0.01 |
0%
|
| Industry Average | 25.5 | AU$-0.26 |
-1 944%
|
| Country Average | 16.8 | AU$-0.17 |
-1 317%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
ImpediMed Ltd
ASX:IPD
|
28.4m AUD | -1.4 | -1.2 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
165.8B USD | 20 | 26.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.7B USD | 54.3 | 58.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
129.4B USD | 24.9 | 40.4 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
109.9B USD | 19.3 | 24 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
94.1B USD | 26.2 | 32.9 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
43.9B EUR | 16.3 | 20.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.9B USD | 26.1 | 43.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.4B USD | 34.6 | 44.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.1B USD | 17.1 | 25.7 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
33.4B USD | 14.1 | 16.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10.7 |
| Median | 16.8 |
| 70th Percentile | 24.5 |
| Max | 6 797.5 |
Other Multiples
ImpediMed Ltd
Glance View
ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.
